Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
Baxter
McKinsey
Medtronic
Dow

Last Updated: December 12, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,305,986

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which drugs does patent 7,305,986 protect, and when does it expire?

Patent 7,305,986 protects AFREZZA and is included in one NDA.

This patent has sixty-one patent family members in eighteen countries.

Summary for Patent: 7,305,986
Title:Unit dose capsules for use in a dry powder inhaler
Abstract: Described are capsules to contain a drug for use in an inhaler. The capsules may be two-part capsules where each half has apertures which may correspond to apertures in the other half. The first half fits snugly within the second half and the two halves may be rotated around their longitudinal axes with respect to each other to produce unlocked and locked positions. In the unlocked position, at least one aperture in the first half aligns with at least one aperture in the second half, which permits introduction of a medicament. In the locked position, at least two apertures in the first half align with at least two apertures in the second half, allowing air to pass through the capsule, releasing the medicament contained therein. Each capsule may have a unique key on each half that only fits with a particular inhaler or identifies the medicament contained therein.
Inventor(s): Steiner; Solomon S. (Mount Kisco, NY), Feldstein; Robert (Yonkers, NY), Fog; Per B. (Bedford Hills, NY), Poole; Trent (South Amherst, MA)
Assignee: MannKind Corporation (Valencia, CA)
Application Number:09/621,092
Patent Claim Types:
see list of patent claims
Dosage form; Delivery;

Drugs Protected by US Patent 7,305,986

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Mannkind AFREZZA insulin recombinant human POWDER;INHALATION 022472-001 Jun 27, 2014 RX Yes No   Start Trial   Start Trial Y   Start Trial
Mannkind AFREZZA insulin recombinant human POWDER;INHALATION 022472-002 Jun 27, 2014 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Mannkind AFREZZA insulin recombinant human POWDER;INHALATION 022472-003 Apr 17, 2015 RX Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,305,986

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 339981   Start Trial
Austria 390944   Start Trial
Australia 2004270204   Start Trial
Australia 2005201843   Start Trial
Australia 2009201564   Start Trial
Australia 2009212849   Start Trial
Australia 7138000   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
Boehringer Ingelheim
Baxter
Moodys
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.